Personally I see an AMGN buyout of CYTK. AMGN is set to begin another phase in their collaboration with CYTK. AMGN has already invested 125 million in omecamtiv mecarbil ( CYTK's lead heart drug ). As part of their agreement, 450 million in additional potential milestones are payable and double digit royalties upon commercialization. CYTK is actively perusing a partner for their ALS drug, which has been showing great results and data will be presented this Friday at the Annual Meeting of the American Academy of Neurology. There is currently no drug on the market that addresses the quality of life for these patients and the potential market is sufficient to warrant a big player jumping on board. I won't go into more detail on the rest of CYTK's pipeline for now as you can look that up when you have time.
AMGEN already holds a 5% stake in CYTK. There is no poison pill in place. Amgen can easily take out CYTK for what they are already committed to provided the trials go well. They can pickup the ALS drug, the Cancer portfolio and the rest of the muscle compounds as a package deal without additional risk capital being allocated over what they already have in place. If AMGN was to pay anything under 8.30 per share, its a winner for them. They could buy CYTK and out license or monetize the other drugs and really make this a sweet deal for them and the stockholders.